http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019057201-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dec8bf963ac22ae0f235698cde519b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b26e17432236aa949f62b08733832285
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f84e76a2d44d18ef7aa15763f3e8fb36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1b612afe34010acc8547b97b2b11d45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1e2ed3a634b72ca3255058f1277c66b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d53be8209a543c8f7712c955503006bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e0b817a688d3486449870409781a198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c17543703370009ec85cd35c762c6af9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68b959893b0b92ca5e0aeda6c991d2a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc9e94a9150b2e0b85da4dff83e3f1e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d49a02b81dfbc05a7f21a6ca0cd5c0d5
publicationDate 2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2019057201-A1
titleOfInvention CRYSTALLINE FORM OF AN INHIBITOR OF THE ESTROGEN RECEPTOR AND PREPARATION METHOD THEREOF
abstract A crystal form of an estrogen receptor inhibitor and a preparation method thereof, specifically, a crystal form of the compound of the formula (I) and a preparation method thereof, and a method for preparing the crystal form for treating breast cancer application.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020108154-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3889136-A4
priorityDate 2017-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015136016-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017162206-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106488767-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103189361-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21893751
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21885
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412224690
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3776
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415810339
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454463663
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6340
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503546
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104741
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3902
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453782864
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164181712
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530548
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513958

Total number of triples: 51.